Immunocore Nears Profitability as KIMMTRAK Sales Hit $115.9M, Pipeline Advances
IMCR sits 20% above its 52-week low of $27.555.
Summary
Immunocore reported Q2 2026 KIMMTRAK net revenues of $115.9M, up 18% YoY, driving a near-breakeven net loss of just $0.8M ($0.02/share) versus a $10.3M loss a year ago. The company is on the cusp of sustained profitability, with $880M in cash providing ample runway. Enrollment in the pivotal Phase 3 TEBE-AM trial in advanced cutaneous melanoma is nearly complete, with data potentially by end of 2026 — a major catalyst that could expand KIMMTRAK's addressable market significantly. Five-year overall survival data presented at AACR showed KIMMTRAK doubled the likelihood of being alive at five years in metastatic uveal melanoma, reinforcing its standard-of-care status. Phase 1 brenetafusp data in advanced melanoma, presented at ASCO, supports the ongoing Phase 3 PRISM-MEL-301 trial in the first-line setting. The combination of commercial execution, near-term pipeline readouts, and a strong balance sheet positions Immunocore for a transformative year ahead.
At the time of this announcement, IMCR was trading at $33.20 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $27.56 to $40.71. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.